Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

The substance of the appeal will have to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
TastyTheElf Member Profile
 
Followed By 65
Posts 5,826
Boards Moderated 0
Alias Born 05/01/11
160x600 placeholder
FMS, GMBL and APM among pre market gainers Seeking Alpha - 1/25/2022 8:42:35 AM
Amarin gains as activist Sarissa raises stake Seeking Alpha - 1/25/2022 6:59:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2022 9:07:19 AM
Amarin sees Q4 and FY21 revenue below consensus; shares down 3% Seeking Alpha - 1/10/2022 7:57:04 AM
Amarin Provides Preliminary 2021 Revenue and Outlook for 2022 GlobeNewswire Inc. - 1/10/2022 7:00:00 AM
Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/4/2022 7:00:00 AM
Amarin jumps after activist Sarissa discloses stake in 13-F filing Seeking Alpha - 11/16/2021 10:52:48 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/16/2021 7:00:00 AM
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific GlobeNewswire Inc. - 11/15/2021 4:30:00 PM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 11/11/2021 7:00:00 AM
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/8/2021 7:00:00 AM
Amarin shares fall after Q3 topline miss, cash position update Seeking Alpha - 11/3/2021 6:40:19 AM
Amarin EPS beats by $0.01, misses on revenue Seeking Alpha - 11/3/2021 6:03:17 AM
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/3/2021 6:00:00 AM
Amarin Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:36:18 AM
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 GlobeNewswire Inc. - 10/20/2021 7:05:00 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/12/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:31:42 AM
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S. GlobeNewswire Inc. - 9/22/2021 9:15:00 AM
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Amarin to Participate in September Investment Conferences GlobeNewswire Inc. - 9/13/2021 6:00:00 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/31/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Societ... GlobeNewswire Inc. - 8/23/2021 3:15:00 AM
TastyTheElf   Monday, 03/30/20 08:42:04 PM
Re: marjac post# 258232
Post # of 367713 
The substance of the appeal will have to rest on that -- the flimsiness of the evidence that Judge Du made the centerpiece of her decision.

Three tiny Japanese trials that had to be combined to create "obviousness" -- with all other trials and opinions ignored. That's what the appeal has to rest on.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences